Biogen: Q3 earnings beat estimates, revenues up 11%, 2026 EPS view tightened
FROM THE WIRE · FINANCE.YAHOO.COM
Biogen BIIB reported third-quarter 2026 adjusted earnings per share (EPS) of $2.62, which beat the Zacks Consensus Estimate of $2.06 per share. Earnings, however, declined 46% year over year due to higher acquired in-process research and development (IPR&D), and upfront and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results above consensus, with new drugs supporting sales growth.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Biogen reported third-quarter 2026 adjusted EPS of $2.62, above the Zacks consensus of $2.06.
- 02Revenues came in at $2.80 billion, up 11% year over year on a reported basis.
- 03Skyclarys, Qalsody, Zurzuvae and drugs acquired from Apellis drove revenue growth.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets